What labs and cardiac imaging should I have as a 68‑year‑old with stable hypertrophic cardiomyopathy and a prior cardiac CT angiogram showing age‑appropriate atherosclerosis?

Laboratory and Cardiac Imaging Recommendations for Stable Hypertrophic Cardiomyopathy with Atherosclerosis

As a 68-year-old with stable HCM and known atherosclerosis, you should have comprehensive laboratory testing including CBC, renal function, liver function, thyroid function, lipid panel, fasting glucose/HbA1c, BNP/NT-proBNP, and troponin T, along with serial echocardiography every 1-2 years and 24-48 hour ambulatory ECG monitoring every 1-2 years. 1, 2, 3

Essential Laboratory Tests

Your routine lab work should include the following core tests to monitor both your HCM and identify any conditions that could worsen your cardiac function:

Standard Metabolic and Hematologic Panel

• Complete blood count to exclude anemia, which can exacerbate symptoms in HCM 1
• Renal function tests (creatinine, GFR) to detect kidney dysfunction that may indicate infiltrative disease or medication effects 1, 3
• Serum electrolytes (sodium, potassium, calcium, magnesium) to identify abnormalities contributing to cardiac dysfunction 1
• Liver function tests (transaminases) to monitor for metabolic disorders and medication effects 1, 3

Cardiovascular Risk Assessment

• Fasting glucose and glycohemoglobin (HbA1c) to screen for diabetes, which exacerbates heart failure 1, 3
• Lipid profile (total cholesterol, LDL, HDL, triglycerides) given your atherosclerosis history 1
• Thyroid function tests (TSH, free T4) since both hyper- and hypothyroidism can cause or worsen heart failure 1, 3

Cardiac Biomarkers

• BNP or NT-proBNP levels, which are associated with cardiovascular events, heart failure progression, and death in HCM 1, 3
• High-sensitivity cardiac troponin T to assess ongoing myocardial injury and risk stratification 3, 1

Important caveat: BNP values in cardiac amyloidosis are typically three to five times higher than in sarcomeric HCM with similar wall thickness, so unexpectedly elevated levels should prompt consideration of infiltrative disease 1, 3

Cardiac Imaging Surveillance

Echocardiography

Serial transthoracic echocardiography every 1-2 years is the cornerstone of HCM monitoring to assess changes in left ventricular systolic and diastolic function, wall thickness, chamber size, and valvular disease 2, 3

Your echocardiogram should specifically evaluate:

• Maximum left ventricular wall thickness in all segments from base to apex 2
• Left ventricular outflow tract (LVOT) gradients at rest and with provocative maneuvers (Valsalva, standing) 2, 3
• Systolic anterior motion of the mitral valve and degree of mitral regurgitation 2
• Left ventricular systolic function (ejection fraction) and diastolic function parameters 2
• Left atrial size and volume 2

Ambulatory ECG Monitoring

24-48 hour ambulatory ECG monitoring every 1-2 years is recommended to detect:

• Nonsustained ventricular tachycardia (NSVT), which increases sudden cardiac death risk 3
• Atrial fibrillation, particularly important at your age with increased risk 3

Given your age (68 years) and stable disease, you have higher risk for atrial fibrillation, which is associated with stroke and adverse outcomes in HCM 3

Coronary Assessment Considerations

Given your age, atherosclerosis history, and HCM diagnosis, coronary angiography (CT or invasive) is recommended if you develop symptoms of myocardial ischemia or before any potential surgical myectomy 3

This is critical because:

• Chest pain in HCM can result from either microvascular dysfunction or epicardial coronary disease 3
• Standard stress testing may not reliably distinguish between these causes 4
• The combination of HCM and coronary artery disease is not uncommon in older patients 4, 5

When to Consider Cardiac MRI

Cardiac MRI with late gadolinium enhancement (LGE) should be considered if:

• There is uncertainty about apical involvement or suspected apical aneurysm 3
• Assessment of myocardial fibrosis extent is needed for risk stratification 3
• Echocardiographic images are inadequate 3
• There is concern for infiltrative disease (amyloidosis) 3

Special Considerations for Your Age Group

At 68 years old with HCM, you should be aware of:

Amyloidosis screening may be warranted if you have features such as bilateral carpal tunnel syndrome, no family history of HCM, or unexpectedly high BNP levels. Bone scintigraphy with 99mTc-DPD can distinguish transthyretin (TTR) amyloidosis from sarcomeric HCM 3, 1

Extended ambulatory monitoring beyond 24-48 hours is reasonable given your age and risk factors for atrial fibrillation, particularly if you are eligible for anticoagulation 3

Common Pitfalls to Avoid

• Do not attribute all symptoms to HCM without excluding coronary disease, especially given your atherosclerosis history 3, 4
• Do not overlook thyroid dysfunction, renal impairment, or anemia as contributors to symptom progression 1, 3
• Do not assume stable disease means no monitoring—serial imaging and biomarkers detect progression before symptoms worsen 2, 3
• Do not rely solely on resting echocardiography for LVOT gradient assessment, as up to 50% of obstructive cases are missed without provocative maneuvers 2